|Bid||0.0000 x 0|
|Ask||0.0000 x 0|
|Day's Range||0.0450 - 0.0480|
|52 Week Range||0.0400 - 0.2800|
|Beta (3Y Monthly)||0.06|
|PE Ratio (TTM)||N/A|
|Earnings Date||Aug. 15, 2018|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
LAS VEGAS , Dec. 5, 2019 /CNW/ -- GB Sciences, Inc. (GBLX) announced the execution of a Binding Letter of Intent for the Sale of 75% of its membership interests in the Company's Las Vegas, Nevada cultivation and production operation. This transaction will significantly reduce the Company's operating expenses, generate near-term working capital, and provide ongoing cashflow to enable the Company to focus solely on its biopharmaceutical and wellness assets. The transaction is the next step in the Company's exit from cannabis cultivation and production.
The Sale, Which Immediately Eliminates Substantial Cash Obligations and Operating Expenses, Is Collateralized by Wellcana Plus's Interest in GB Sciences Louisiana. LAS VEGAS , Nov. 18, 2019 /CNW/ -- GB Sciences, Inc. (GBLX) completed the sale on November 15, 2019 of its 50% membership interest in GB Sciences Louisiana, LLC to Wellcana Plus, LLC, an affiliate of Wellcana Group, LLC who owns the other 50% interest. The sale immediately eliminates current cash obligations due from GB Sciences as well as the Company's share of operating expenses going forward.
LAS VEGAS, Oct. 9, 2019 /CNW/ -- GB Sciences, Inc. (OTCQB:GBLX - News) is featured in the October 2019 edition of the Marijuana Business Magazine. Dr. Andrea Small-Howard, GB Sciences' Chief Science Officer and Director, explains why GB Sciences is well-positioned to provide research-supported product formulations for both market segments.
LAS VEGAS, Sept. 17, 2019 /CNW/ -- GB Sciences, Inc. (OTCQB:GBLX - News), on Friday, September 13, 2019, filed an 8k announcing the sale of its 50% ownership stake in GB Sciences Louisiana, LLC. The stake will be purchased by Wellcana Plus LLC, affiliated through its managers with the group which holds the other 50% of the Louisiana operations. Expected to close by the end of October 2019, the sale is for $16 million to GB Sciences, $7 million in cash at closing, $1 million in cash within 60 days of closing, and the remaining $8 million as an earn out. The actual proceeds realized through the earn out and the timing of those proceeds will depend upon the profitability of the Louisiana operations. The sale will greatly reduce the current and future burn rate of the Company and allow it to focus on achieving profitability, seeking a DEA license, and implementing GMP, a set of regulations promulgated by the US Food and Drug Administration to ensure quality control in the manufacture of pharmaceuticals, dietary supplements and natural health products among other substances, at its Las Vegas, Nevada location.
LAS VEGAS , Sept. 3, 2019 /CNW/ -- GB Sciences, Inc. (OTCQB: GBLX) today announced that it has received notification from the U.S. Drug Enforcement Agency (DEA) that prior to making any decisions on the ...
LAS VEGAS, Aug. 28, 2019 /CNW/ -- GB Sciences, Inc. (OTCQB:GBLX - News) today announced the appointment to GB Sciences' executive team of Darin Carpenter as the company's new Executive Vice President for Operations and General Manager, bringing his extensive and nationally-recognized experience streamlining production, improving product quality, and increasing profitability to GBS. In his new role, Mr. Carpenter will design and implement business strategies, marketing, manage the company's cultivation and manufacturing operations, create and maintain tight budgets, and take the lead in monitoring and improving company performance and capital.
Education program includes evidence-based review of FDA-registered human clinical trial data supporting the use of cannabis to treat approved medical conditions. LAS VEGAS, Aug. 7, 2019 /CNW/ -- GB Sciences, Inc. (OTCQB:GBLX - News) announced that its subsidiary GB Sciences Louisiana will hold a series of seminars in August, in partnership with state-approved medical cannabis pharmacies and the LSU AgCenter, to further educate Louisiana physicians and pharmacists about the new medical cannabis products that the company will launch in coming months.
BATON ROUGE, La. , Aug. 6, 2019 /CNW/ -- GB Sciences Louisiana (OTCQB: GBLX) today announced that its medical cannabis products, developed in partnership with LSU AgCenter's Therapeutic Cannabis Program, ...
LAS VEGAS , July 17, 2019 /CNW/ -- GB Sciences, Inc. (OTCQB: GBLX), through its subsidiary, GBS Global Biopharma, Inc. ("GBS", Ottawa, CANADA ), has filed a novel patent application to protect ...
Oral thin films provide a convenient and accurate delivery system with increased bioavailability of cannabis active ingredients for patients LAS VEGAS , June 11, 2019 /CNW/ -- GB Sciences, Inc. (OTCQB:GBLX) ...
OTTAWA, Ontario, May 28, 2019 /CNW/ -- GBS Global Biopharma, Inc. ("GBS Global"), a Canadian-based subsidiary of GB Sciences, Inc. (OTCQB:GBLX - News), announced preclinical studies on their proprietary chronic-neuropathic pain formulations in collaboration with the National Research Council ("NRC") Canada under the direction of Dr. Lee Ellis at NRC laboratories in Halifax, Nova Scotia. Growing public and government concerns regarding opioid abuse make novel pain treatments a promising field of research and development.
Expedites innovative cannabinoid medicine program, covering 60 disease and health conditions including Parkinson's Disease, neuropathic pain and cardiac hypertrophy LAS VEGAS , March 19, 2019 /CNW/ -- GB ...
Many tourists travel aboard for vacations to see dazzling landscapes and bustling city-life and in turn, tourism drives revenue for many businesses such as food, retail, and hospitality, but now it is also helping bolster the cannabis industry. Colorado, which saw 82.4 million travelers in 2016, is among the very few regions to legalize cannabis entirely. A survey conducted by Colorado Tourism reported that the 12 million or approximately 15% of those travelers participated in marijuana-related activities.
In November last year, GB Sciences Inc. (OTCMKTS:GBLX) agreed to work together with Louisiana State University Agricultural Center focusing on cannabis. Notably, the two institutions would cooperate in research and development on cannabis with a keen eye on its therapeutic properties. The partnership has hit the first milestone with the maiden harvesting of cannabis. Leveraging […] The post GB Sciences Hits Milestone After Teaming With LSU Agricultural Research Center appeared first on Market Exclusive.
LAS VEGAS, Jan. 16, 2019 /CNW/ -- GB Sciences, Inc. (OTCQB:GBLX - News) announced the harvest of the first test cannabis crop in the company's nationally-recognized collaboration with Louisiana State University Agricultural Center. On November 16, the Louisiana Department of Agriculture and Forestry took possession of extract samples for testing and expects to complete testing by mid-February. Once GBSL extract passes two tiers of tests, the company will make available the first-ever legal cannabis products to Louisiana patients.
On November 9 th , GB Sciences hosted an open mic-dialogue with key stakeholders in the cannabis industry that focused on addressing medical patients' needs through improved standardization and innovation ...